| 000 | 02934cam a2200349 4500500 | ||
|---|---|---|---|
| 005 | 20250121154620.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aGiavina-Bianchi, Mara _eauthor |
| 700 | 1 | 0 |
_a Giavina-Bianchi, Pedro _eauthor |
| 700 | 1 | 0 |
_a Sotto, Mirian Nacagamo _eauthor |
| 700 | 1 | 0 |
_a Rodig, Scott _eauthor |
| 700 | 1 | 0 |
_a Mihm Jr, Martin _eauthor |
| 700 | 1 | 0 |
_a Festa Neto, Cyro _eauthor |
| 700 | 1 | 0 |
_a Duncan, Lyn M. _eauthor |
| 700 | 1 | 0 |
_a Kalil, Jorge _eauthor |
| 245 | 0 | 0 | _aNodular primary cutaneous melanoma is associated with PD-L1 expression |
| 260 | _c2020. | ||
| 500 | _a75 | ||
| 520 | _aBackground: In previous studies, patients with Stage III melanomas expressing PD-L1 in more than 5% of their neoplastic cells had improved recurrence-free survival with anti-PD1 adjuvant therapy. Objectives: We examined PD-L1 expression as a possible biomarker of primary cutaneous melanomas in the vertical growth phase. Materials and Methods: This was a retrospective study including 66 patients with invasive primary cutaneous melanomas. We assessed patient clinical and histopathological data and performed immunohistochemical assays with melanoma specimens from the patients to evaluate PD-L1, PD-1, CD3, CD8 and FoxP3 expression. Results: We observed PD-L1 expression in 21% (14/66) of our samples, and this expression correlated with increased melanoma thickness (p = 0.002) and nodular-type melanoma (p = 0.001). After adjusting for tumor thickness using a logistic regression test, the association of PD-L1 with nodular-type melanoma persisted. Nodular-type melanoma was 6.48 times more likely to be positive for PD-L1 than other histological types (p = 0.014; 95% CI: 1.46-28.82). As expected, PD-L1 expression correlated with the number of PD-1-expressing cells in the tumor-infiltrating lymphocyte population (p = 0.04). No correlation with PD-L1 was observed for age, sex, tumor site, skin phototype, ulceration status, sentinel lymph node status, metastasis development or survival. Regarding the immune profile of the tumor-infiltrating lymphocytes of PD-L1-positive and -negative groups, no significant differences were observed in the numbers of CD3 + , CD8 + FoxP3-, CD8-FoxP3+ and CD8 + FoxP3+ cells by immunohistochemistry. Conclusion: Nodular-type melanoma is associated with PD-L1 expression and may be a suitable candidate for adjuvant therapy of primary melanomas treated with immunotherapy. | ||
| 690 | _anodular melanoma | ||
| 690 | _atumor infiltrating lymphocytes | ||
| 690 | _aPD-1 | ||
| 690 | _aPD-L1 | ||
| 690 | _atumor microenvironment | ||
| 690 | _aCD8 | ||
| 690 | _aBreslow index | ||
| 690 | _aFoxP3 | ||
| 690 | _aCD3 | ||
| 786 | 0 | _nEuropean Journal of Dermatology | 30 | 4 | 2020-07-01 | p. 352-357 | 1167-1122 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2020-4-page-352?lang=en&redirect-ssocas=7080 |
| 999 |
_c602798 _d602798 |
||